Jul
22
Jan
31
NICoE Deputy Director Receives Department of Defense's Highest Civilian Honor
The work of one of the Department of Defense’s foremost experts on the treatment of traumatic brain injury was recently honored with the department's highest award given to career DOD civilian employees.
COVID-19 Vaccine Training Materials available from the CDC
Find below information and resources on the COVID-19 Vaccination Program from the Defense Health Agency Immunization Healthcare Division. This information is geared toward health care personnel in the Department of Defense (DOD). This page is reviewed daily and more content is added as soon as it becomes available...
DHA-IPM 20-004: DOD Coronavirus Disease 2019 (COVID-19) Vaccination Program Implementation (June 16, 2022)
Information Paper on Novavax COVID-19 Vaccine (July 25, 2022)
Novavax COVID-19 Vaccine: Information on Fetal Cell/Fetal Tissue (July 22, 2022)
Note: Right-click and save these documents to your desktop in order to fill them out and add digital signature.
Note: This vaccine is authorized for emergency use in people 12 and older.
Note: Per the FDA and CDC, the FDA‐approved monovalent COMIRNATY (COVID‐19 Vaccine, mRNA) and the FDA‐authorized monovalent Pfizer‐BioNTech COVID‐19 Vaccine under Emergency Use Authorization (EUA) have the same formulation and can be used interchangeably to provide the COVID‐19 vaccination series..
Note: The Pfizer-BioNTech vaccine for 5–11-year-olds is a new product configuration with new packaging, new preparation, and a new national drug code (NDC). The previously existing product for adults and adolescents should not be used in children younger than 12.
Note: The Pfizer-BioNTech COVID-19 Vaccine has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a 3-dose primary series to individuals 6 months through 4 years of age.
Back to top of page
Moderna Bivalent COVID‐19 Vaccine Information Fact Sheet for Health Care Personnel (Oct. 12, 2022) (bivalent booster doses for ages 6 and older)
Moderna Bivalent COVID‐19 Vaccine Information Fact Sheet for Recipients and Caregivers (Oct. 12, 2022) (primary series and bivalent booster doses for ages 6 and older)
Note: SPIKEVAX (COVID-19, mRNA) and Moderna COVID-19 Vaccine supplied in multiple-dose vials with a red cap and a label with a light blue border intended for use in individuals 12 years of age and older should not be used in individuals 6 months through 11 years of age because of the potential for vaccine administration errors, including dosing errors..
Note: Moderna COVID-19 Vaccine supplied in multiple-dose vials with a dark blue cap and a label with a magenta border is intended for use in individuals 6 months through 5 years of age and should not be used in individuals 6 years of age and older.
Note: The dates on the bottom of the documents are always the dates of the last updates. The documents in the links above update automatically when the FDA releases new versions.
Bullet Background Paper on Pfizer-BioNTech COVID-19 Vaccine Buffer Solution (Nov. 8, 2021)
U.S. COVID-19 Vaccine Product Information (Aug. 31, 2022)
Transporting Vaccine for Vaccination Clinics Held at Satellite, Temporary or Off-Site Locations (Aug. 24, 2021)
Temperature Log when Transporting Vaccine at Refrigerated Temperatures (Feb. 18, 2021)
Vaccine Storage Troubleshooting Record for Temperature Excursions (August 2021)
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 (Aug. 13, 2021)
Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021 (Aug. 27, 2021)
The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021 (Nov. 5, 2021)
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022 (July 1, 2022)
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 (Nov. 11, 2022)
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021 (Sept. 24, 2021)
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021 (March 2, 2021)
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 (April 27, 2021)
A warrior care coordinator shares how she supports recovering service members, their families and caregivers.
Recommended Content:
The appearance of hyperlinks does not constitute endorsement by the Department of Defense of non-U.S. Government sites or the information, products, or services contained therein. Although the Defense Health Agency may or may not use these sites as additional distribution channels for Department of Defense information, it does not exercise editorial control over all of the information that you may find at these locations. Such links are provided consistent with the stated purpose of this website.